With 3.58 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.97 million shares. During the session, the Medical Care Facilities company that operates in wider Healthcare sector, reached to the highest price of $2.17 whereas the lowest price it dropped to was $2.03. The 52-week range on AGL shows that it touched its highest point at $9.30 and its lowest point at $1.50 during that stretch. It currently has a 1-year price target of $2.67. Beta for the stock currently stands at 0.54.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AGL was up-trending over the past week, with a rise of 12.57%, but this was down by -2.71% over a month. Three-month performance dropped to -31.75% while six-month performance fell -62.61%. The stock lost -75.09% in the past year, while it has gained 13.16% so far this year. A look at the trailing 12-month EPS for AGL yields -0.82 with Next year EPS estimates of -0.35. For the next quarter, that number is -0.22. This implies an EPS growth rate of -17.47% for this year and 37.96% for next year.
Float and Shares Shorts:
At present, 411.96 million AGL shares are outstanding with a float of 303.29 million shares on hand for trading. On 2024-12-13, short shares totaled 29.79 million, which was 723.0 higher than short shares on 1731628800. In addition to Mr. Steven Jackson Sell as the firm’s President, CEO & Director, Mr. Jeffrey Alan Schwaneke CPA serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 1.0517299 of AGL’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, AGL reported revenue of $1450932000.0 and operating income of -$133508000.0. The EBITDA in the recently reported quarter was -$109182000.0 and diluted EPS was -$0.29.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AGL since 10 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AGL analysts setting a high price target of 6.0 and a low target of 1.75, the average target price over the next 12 months is 2.86471. Based on these targets, AGL could surge 179.07% to reach the target high and fall by -18.6% to reach the target low. Reaching the average price target will result in a growth of 33.24% from current levels.
Analysts have provided yearly estimates in a range of -$0.55477 being high and -$0.59114 being low. For AGL, this leads to a yearly average estimate of -$0.56386.
